Author Page for Toru Mukohara

Phase 2 Study of Nivolumab Plus Bevacizumab Plus Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer

Number of pages: 34 Posted: 04 May 2021

Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano and Toshimi Takano

Toranomon Hospital - Department of Medical Oncology, Showa University - Advanced Cancer Translational Research Institute, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, Hyogo Cancer Center - Department of Medical Oncology, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology

Downloads 106 (659,652)

Abstract:

2.

Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial

Number of pages: 51 Posted: 03 Mar 2022

Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano and Toshimi Takano

Toranomon Hospital - Department of Medical Oncology, affiliation not provided to SSRN, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, Hokkaido University - Hokkaido University Hospital, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, affiliation not provided to SSRN, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology

Downloads 48 (1,109,210)

Abstract:

3.

Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study

Number of pages: 38 Posted: 24 Oct 2025

Miki Hayakawa, Hiromichi Nakajima, Kenichi Harano, Shogo Watanabe, Saki Tsuchimochi, Mao Uematsu, Misao Fukuda, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Masashi Wakabayashi, Kazuaki Takahashi, Hiroshi Tanabe and Toru Mukohara

affiliation not provided to SSRN, affiliation not provided to SSRN, National Cancer Center Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, National Cancer Center Hospital East, National Cancer Center Hospital, affiliation not provided to SSRN, National Cancer Center Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN and National Cancer Center Hospital East - Department of Breast and Medical Oncology

Downloads 40 (1,222,651)

Abstract:

4.

Prophylaxis against pneumocystis pneumonia in patients with breast cancer who develop lymphopenia during perioperative treatment with dose-dense doxorubicin and cyclophosphamide

Number of pages: 27 Posted: 10 Mar 2026

Akari Nakamura, Kaede Baba, Kanako Kusuhara, Shu Kato, Yoichi Naito, Nobuaki Matsubara, Ako Hosono, Chihiro Kondoh, Kenichi Harano, Hiromichi Nakajima, Chikako Funasaka, Keiji Okinaka and Toru Mukohara

affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and National Cancer Center Hospital East - Department of Breast and Medical Oncology

Downloads 23 (1,424,331)

Toru Mukohara

National Cancer Center Hospital East - Department of Breast and Medical Oncology

4

217

0

Scholarly Papers (4)

Phase 2 Study of Nivolumab Plus Bevacizumab Plus Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer

Abstract:

Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial

Abstract:

Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study

Abstract:

Prophylaxis against pneumocystis pneumonia in patients with breast cancer who develop lymphopenia during perioperative treatment with dose-dense doxorubicin and cyclophosphamide

Abstract: